MicroRNA in Solid Tumor and Hematological Diseases
MicroRNAs (miRNAs), which are a type of short non-coding RNA, are involved in number of processes, such as differentiation, development, inflammation, immune response, and cancer. miRNAs, which act as oncogenes or tumor suppressor genes, can control and regulate the translation and stability of targ...
में बचाया:
अन्य लेखक: | |
---|---|
स्वरूप: | इलेक्ट्रोनिक पुस्तक अध्याय |
भाषा: | अंग्रेज़ी |
प्रकाशित: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
विषय: | |
ऑनलाइन पहुंच: | DOAB: download the publication DOAB: description of the publication |
टैग: |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|
MARC
LEADER | 00000naaaa2200000uu 4500 | ||
---|---|---|---|
001 | doab_20_500_12854_78842 | ||
005 | 20220224 | ||
003 | oapen | ||
006 | m o d | ||
007 | cr|mn|---annan | ||
008 | 20220224s2022 xx |||||o ||| 0|eng d | ||
020 | |a books978-3-0365-3089-5 | ||
020 | |a 9783036530895 | ||
020 | |a 9783036530888 | ||
040 | |a oapen |c oapen | ||
024 | 7 | |a 10.3390/books978-3-0365-3089-5 |c doi | |
041 | 0 | |a eng | |
042 | |a dc | ||
072 | 7 | |a GP |2 bicssc | |
100 | 1 | |a Lovat, Francesca |4 edt | |
700 | 1 | |a Lovat, Francesca |4 oth | |
245 | 1 | 0 | |a MicroRNA in Solid Tumor and Hematological Diseases |
260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
300 | |a 1 electronic resource (226 p.) | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
520 | |a MicroRNAs (miRNAs), which are a type of short non-coding RNA, are involved in number of processes, such as differentiation, development, inflammation, immune response, and cancer. miRNAs, which act as oncogenes or tumor suppressor genes, can control and regulate the translation and stability of target messenger RNA, contributing to cancer pathogenesis. Despite the progress that has been made in discovering the mechanisms of how miRNAs function in tumors, many questions and aspects of miRNA biology and processing still remain to be determined. This Special Issue, titled "MicroRNA in Solid Tumor and Hematological Diseases", provides a panorama of the existing knowledge gaps and potential uses of microRNAs to predict clinical outcome or response to therapies and provides evidence to explain their role as biomarkers to modulate the biological pathways that are critical for cancer development and progression. It includes eleven peer-reviewed papers that cover the role of microRNAs in different tumor types and their potential applications in diagnosis and clinical approaches. | ||
540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
546 | |a English | ||
650 | 7 | |a Research & information: general |2 bicssc | |
653 | |a bladder cancer | ||
653 | |a urine | ||
653 | |a miRNA | ||
653 | |a reference miRNA | ||
653 | |a normalizer | ||
653 | |a RT-qPCR | ||
653 | |a miR-139-5p | ||
653 | |a miR-139-3p | ||
653 | |a renal cell carcinoma (RCC) | ||
653 | |a microRNA | ||
653 | |a tumor suppressor | ||
653 | |a paxillin (PXN) | ||
653 | |a acute myeloblastic leukemia | ||
653 | |a acute lymphoblastic leukemia | ||
653 | |a colorectal cancer | ||
653 | |a amino acid transporters | ||
653 | |a LAT1 | ||
653 | |a ASCT2 | ||
653 | |a miRNAs | ||
653 | |a microRNAs | ||
653 | |a GI cancers | ||
653 | |a targeted therapy | ||
653 | |a drug resistance | ||
653 | |a miR-7 | ||
653 | |a gene expression | ||
653 | |a cancer cell | ||
653 | |a prognosis | ||
653 | |a follicular lymphoma | ||
653 | |a marginal zone lymphoma | ||
653 | |a Waldenström's macroglobulinemia | ||
653 | |a hairy cell leukemia | ||
653 | |a primary cutaneous follicle center lymphoma | ||
653 | |a normal B-cell development | ||
653 | |a therapeutic target | ||
653 | |a diagnosis | ||
653 | |a solid cancer | ||
653 | |a post-transcriptional regulation | ||
653 | |a hepatocellular carcinoma | ||
653 | |a Hippo kinase | ||
653 | |a Yes-associated protein | ||
653 | |a liver disease | ||
653 | |a cancer therapy | ||
653 | |a PDAC | ||
653 | |a survival | ||
653 | |a expression profiling | ||
653 | |a ovarian cancer | ||
653 | |a epithelial ovarian cancer | ||
653 | |a liquid biopsy | ||
653 | |a circulating miRNAs | ||
653 | |a drug response | ||
653 | |a personalized medicine | ||
653 | |a chemotherapy | ||
653 | |a n/a | ||
856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/4936 |7 0 |z DOAB: download the publication |
856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/78842 |7 0 |z DOAB: description of the publication |